“We don’t make pharmaceuticals anymore and if
Post# of 154682
(Total Views: 611)
Posted On: 04/09/2025 12:11:50 AM
“We don’t make pharmaceuticals anymore and if we have problems like wars or anything else, we need steel, we need pharmaceuticals.”
25% Tariffs coming for drug imports.
Google:
Indian pharmaceutical companies play a crucial role in the U.S. healthcare system. In 2022, they accounted for four out of every ten prescriptions filled in the U.S. According to reports, medicines from Indian firms saved the U.S. healthcare system USD 219 billion in 2022 alone, and USD 1.3 trillion between 2013 and 2022. Over the next five years, generics from India are projected to deliver an additional USD 1.3 trillion in savings.
Been saying for a while, do not forget the add-on benefits Leronlimab provides. Not traditonal model "market size" for a share price. Leronlimab will give Cytodyn unprecedented insurance, overhead & operational savings. This just out, is right up that alley.
Looks like a GF/GSK(ViiV)Pfizer could be up against some competition from India or a big collaboration perhaps. They all know the political assist funding game available for developing Leronlimab.
Tax breaks:
Brick n mortar, local/state/fed, property, training, supplies, etc., etc.. Every state would love to be home to manufacturing the "cancer-free" drug.
Vancouver, Washington & constituents will need to step up very shortly on Leronlimab.
25% Tariffs coming for drug imports.
Google:
Indian pharmaceutical companies play a crucial role in the U.S. healthcare system. In 2022, they accounted for four out of every ten prescriptions filled in the U.S. According to reports, medicines from Indian firms saved the U.S. healthcare system USD 219 billion in 2022 alone, and USD 1.3 trillion between 2013 and 2022. Over the next five years, generics from India are projected to deliver an additional USD 1.3 trillion in savings.
Been saying for a while, do not forget the add-on benefits Leronlimab provides. Not traditonal model "market size" for a share price. Leronlimab will give Cytodyn unprecedented insurance, overhead & operational savings. This just out, is right up that alley.
Looks like a GF/GSK(ViiV)Pfizer could be up against some competition from India or a big collaboration perhaps. They all know the political assist funding game available for developing Leronlimab.
Tax breaks:
Brick n mortar, local/state/fed, property, training, supplies, etc., etc.. Every state would love to be home to manufacturing the "cancer-free" drug.
Vancouver, Washington & constituents will need to step up very shortly on Leronlimab.
(2)
(0)